Fusarium Ear Infections Are Becoming More Common and Harder to Treat, New Review Finds

A new systematic review and meta-analysis pulls together more than half a century of evidence on Fusarium-caused fungal ear infections and concludes that the condition is being reported more often, resists most standard antifungal drugs, and frequently leaves patients with hearing loss as part of the clinical picture.

Most people who have had an ear infection have been told that bacteria are the usual culprit. But there is another, less familiar category of ear infection caused by molds and yeasts. The medical name for fungal infection of the outer ear and ear canal is otomycosis, and one of the genera responsible for it is Fusarium, a group of filamentous fungi best known for causing crop diseases in agriculture. When Fusarium gets into a human ear canal, the infection can be unusually stubborn.

A multinational research group led from Iran, with collaborators in Austria, Serbia, and the United States, set out to summarize what is currently known about Fusarium otomycosis. Their systematic review and meta-analysis was published in Current Medical Mycology, and it offers one of the most comprehensive looks to date at how common the infection is, how it presents, and what actually works to treat it.

Background: Why the Researchers Looked at This

Otomycosis, the medical term for a fungal infection of the outer ear and the ear canal, is more common in warm, humid climates and in people who use cotton swabs aggressively, swim often, or have small breaks in the skin lining the ear canal. The classic culprits are species of Aspergillus and Candida, both of which are well characterized and reasonably responsive to topical antifungals. Fusarium is different. It is a so-called emerging fungal pathogen, more often discussed in the context of severe eye infections and bloodstream infections in cancer patients than in the context of ear health.

The clinical concern is twofold. First, Fusarium is increasingly being identified in ear swabs as molecular tools improve, which means cases that used to be lumped under generic otomycosis are now getting a more specific diagnosis. Second, Fusarium species are notoriously hard to kill. Many strains are intrinsically resistant to the classic azole and polyene antifungals that doctors typically reach for first. The authors wanted to pull together what the published literature actually shows about who gets these infections, what symptoms they cause, and which treatments work.

Some terminology helps when reading the rest of this. Otitis externa is inflammation of the outer ear canal. Otorrhea is discharge from the ear. Topical antifungals are creams, drops, or ointments applied directly into the ear, as opposed to systemic antifungals taken as pills or by IV. A pooled prevalence in a meta-analysis is the rate that emerges when you combine results from multiple smaller studies into one statistical estimate.

How the Study Was Done

The researchers searched five scientific databases for articles published between 1966 and July 2023. Search terms covered the genus name, related concepts like fusariosis and otomycosis, and broader ear infection terms such as otitis externa, ear disorder, and ear infection. After screening titles and abstracts, 354 papers advanced to full-text review. The bulk of those were then excluded as either off-topic or as one-off case reports of a single patient, neither of which gives reliable population-level information. Eleven studies survived this filter and were included in the final review.

From those 11 studies, the team extracted information on patient characteristics, including age, underlying conditions like diabetes or recent ear trauma, and risk factors such as prior ear infections. They cataloged the most commonly reported symptoms, the diagnostic methods that were used, and the antifungal treatments that were tried, along with how patients fared. The team then ran a meta-analytic estimate of how often Fusarium specifically shows up in ear infection cases.

What the Researchers Found

When the data from the included studies were pooled, the prevalence of Fusarium-caused otomycosis was estimated at 2.3 percent, with a 95 percent confidence interval of 1.2 to 3.7 percent. That is not a huge slice of all ear infections, but it is a meaningful and apparently growing share, especially given how poorly this fungus responds to standard antifungals. In other words, even if the absolute number is small, the consequences for any one affected patient can be severe.

The patient picture that emerged is mixed. Fusarium otomycosis was reported in otherwise healthy individuals, not just immunocompromised people, although diabetes, ear trauma, and prior ear infections came up repeatedly as risk factors. The most common symptoms reported across studies were itching inside the ear canal, ear pain, discharge from the ear, hearing loss, and visible inflammation of the external ear canal. The hearing loss observed in these cases is typically conductive, meaning it is caused by debris and inflammation blocking sound transmission rather than by damage to the inner ear, but persistent or recurrent infections can leave longer-lasting hearing problems.

On the diagnostic side, most of the included studies still relied on traditional methods such as microscopy and culture. The authors flag this as a limitation, because Fusarium is easy to misidentify under the microscope, and accurate species-level identification often requires molecular tools that can sequence the fungal DNA. The handful of studies that did use molecular methods produced more confident identifications.

Treatment was where the picture turned cautiously hopeful. Fusarium species commonly resist many of the antifungal drug classes that doctors use against more familiar molds and yeasts. Even so, the review notes that several topical agents showed promise in the included studies, including terbinafine, voriconazole, amphotericin B, and natamycin. Combined with thorough mechanical cleaning of the ear canal, these drugs were associated with successful clearance in many cases, even though the optimal regimen, dose, and duration are still not well defined.

The authors conclude that Fusarium otomycosis is an emerging clinical entity that warrants more attention. Awareness among ear, nose, and throat physicians, plus access to better diagnostic tools and a willingness to use less common antifungals, are likely to matter more in the next decade than they did in the last.

What It Means for People with Hearing Loss

For most readers the practical takeaway is not that Fusarium ear infections are common, but that ear infections are not always bacterial. If you have an ear infection that is not getting better on standard antibiotic ear drops, especially one with thick debris, persistent itching, or hearing loss that is not fading after a week or two, it is reasonable to ask whether a fungal cause has been considered. People with diabetes, those who swim a lot, and those who have had repeated ear infections in the past are at higher risk and should be especially vigilant about persistent symptoms.

For people who have already lived through a stubborn ear infection, hearing loss can linger after the inflammation clears. Sometimes that hearing comes back fully once the canal is cleaned and healed. Sometimes it does not. Following up with an audiologist after a complicated ear infection, particularly when the infection has needed weeks of topical treatment, helps confirm whether residual hearing loss is conductive, sensorineural, or a mix.

When Stubborn Ear Infections Leave Lingering Hearing Loss, a Form Factor That Sits Outside the Canal Helps

If a fungal ear infection has left you with persistent hearing loss even after the inflammation has cleared, the next decision is amplification. After a long course of topical antifungal drops and ear canal cleanings, many people understandably want a hearing aid that does not push deep into the canal and trap moisture and debris.

Panda Quantum is a 16-channel receiver-in-canal device, which means the bulk of the hearing aid sits behind the ear and only a thin wire and a small receiver enter the canal. That keeps the canal more open than an in-the-canal device and is generally more comfortable for skin that has been recently inflamed. Panda Quantum offers up to 80 hours of total battery life with the case, Bluetooth for phone calls, TV, and music, plus the Panda app-based in-ear hearing test, which pairs with the device after delivery, runs a frequency-specific hearing test through the hearing aid itself, and automatically programs the gain and frequency response to match your audiogram, similar to a clinical audiologist fitting. The device comes with a 5-year warranty and a 45-day return window. Learn more at pandahearing.com/products/panda-hearing-aids-quantum.

A reasonable caveat: OTC hearing aids are approved for adults with mild-to-moderate hearing loss. If a stubborn ear infection has left more severe damage, or if the loss is mixed with ongoing medical issues in the ear canal, a clinical audiologist and ENT physician are still the right starting point.

Limitations of This Research

A meta-analysis of 11 studies covering nearly six decades is a useful starting point, but it is not the final word. The included studies varied in size, design, geography, and diagnostic methods. Most relied on conventional culture and microscopy rather than molecular identification, which raises the possibility that some Fusarium cases were missed and some non-Fusarium cases were misclassified. Treatment data were largely observational, drawn from case series rather than randomized trials, so the authors can describe what appeared to work but cannot rank the antifungals against each other with high confidence. The pooled prevalence estimate also has a wide confidence interval, reflecting genuine uncertainty about how common this infection really is across different parts of the world.

No clear conflicts of interest or commercial sponsorships are highlighted in the available metadata for the review.

What to Do With This

Fungal ear infections are a relatively small slice of all ear infections, but Fusarium otomycosis is a clear example of how an emerging pathogen can complicate something that used to feel routine. The review reminds clinicians and patients alike that an ear infection that is not responding to standard care, or that keeps coming back, deserves a more thorough workup that includes the possibility of a fungal cause. For patients living with the long shadow of a stubborn ear infection, that means staying engaged with both the medical workup and, if needed, the audiology side of the recovery.

Haghani I, Taheri Rizi Z, Kermani F, Javidnia J, Ghazanfari M, Roohi B, Ghafari M, Hedayati MT, Khojasteh S, Shokoohi G, Nosratabadi M, Abastabar M, Otasevic S, Farokhi Z, Badali H, Al-Hatmi AMS. Challenges and future strategies for management of otomycosis caused by Fusarium species: A systematic review and meta-analysis. Current Medical Mycology. 2025;11. Retrieved from PubMed. https://doi.org/10.22034/cmm.2025.345494.172